Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis

समान संसाधन

• ERS Special Article. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial
  द्वारा: Velásquez, Gustavo E., और अन्य
  प्रकाशित: (2018)
• Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial
  द्वारा: Milstein, Meredith, और अन्य
  प्रकाशित: (2016)
• Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis
  द्वारा: Peloquin, C. A., और अन्य
  प्रकाशित: (2017)
• Erratum for Peloquin et al., “Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis”
  द्वारा: Peloquin, C. A., और अन्य
  प्रकाशित: (2017)
• Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
  द्वारा: te Brake, Lindsey H. M., और अन्य
  प्रकाशित: (2019)